阿替唑单抗
贝伐单抗
医学
肿瘤科
单克隆
临床试验
内科学
梅德林
癌症研究
单克隆抗体
作者
Kazuomi Ueshima,Kaoru Tsuchiya,Tatsuya Yamashita,Shigeo Shimose,Kazushi Numata,Yuzo Kodama,Shinji Itoh,Yasuhito Tanaka,Hidekatsu Kuroda,Kazuyoshi Ohkawa,Teiji Kuzuya,Masafumi Ikeda,Youhei Kooka,Hiroshi Aikata,Atsushi Hiraoka,Michihisa Moriguchi,Ryosuke Tateishi,Sadahisa Ogasawara,Kouji Yamamoto,Masatoshi Kudo
摘要
BACKGROUND AND AIMS: The phase II REPLACEMENT study showed promising clinical benefit from atezolizumab plus bevacizumab in transcatheter arterial chemoembolization (TACE)-naïve patients with intermediate-stage hepatocellular carcinoma (HCC) beyond up-to-7 criteria, meeting its primary endpoint of progression-free survival (PFS). Here, we report the final overall survival (OS) analysis. METHODS: Enrolled patients were naïve to TACE with unresectable intermediate-stage HCC beyond up-to-7 criteria, had Child-Pugh A, Eastern Cooperative Oncology Group performance status 0/1 and received no previous systemic therapy. Atezolizumab 1200 mg and bevacizumab 15 mg/kg were administered every 3 weeks. The primary endpoint was the 6-month PFS rate by modified Response Evaluation Criteria in Solid Tumours for HCC (mRECIST); secondary endpoints included OS, PFS by RECIST version 1.1, objective response rate (ORR) and safety. RESULTS: Overall, 74 patients were enrolled between December 2020 and September 2021. At the clinical cut-off date (March 31, 2024), median follow-up was 33.6 months. Median PFS by mRECIST was 9.1 months (95% CI 7.1-10.2). Median OS was 33.8 months (95% CI 22.6-not estimable). ORR was 40.5% (95% CI 29.3-52.6), with 12.2% of patients having a complete response. Overall, 82.4% of patients received subsequent therapy. All-cause adverse events (AEs) were observed in 98.6% of patients, most commonly hypertension (71.6%) and proteinuria (54.1%). Grade 3/4 AEs occurred in 43.2% of patients; no Grade 5 AEs were reported. CONCLUSIONS: These results show that atezolizumab plus bevacizumab can be an alternative treatment option for patients with intermediate-stage HCC beyond up-to-7 criteria who are deemed unsuitable for TACE. TRIAL REGISTRATION: jRCTs071200051.
科研通智能强力驱动
Strongly Powered by AbleSci AI